Comparing Century Therapeutics (NASDAQ:IPSC) & Lyell Immunopharma (NASDAQ:LYEL)

Lyell Immunopharma (NASDAQ:LYEL) and Century Therapeutics (NASDAQ:IPSC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, earnings, dividends and profitability.

Volatility and Risk

Lyell Immunopharma has a beta of -0.04, indicating that its stock price is 104% less volatile than the S&P 500. Comparatively, Century Therapeutics has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500.

Institutional & Insider Ownership

66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are held by institutional investors. 6.2% of Lyell Immunopharma shares are held by company insiders. Comparatively, 2.4% of Century Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Lyell Immunopharma and Century Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lyell Immunopharma	-1,701,066.75%	-101.30%	-76.41%
Century Therapeutics	N/A	-49.51%	-38.09%

Analyst Ratings

This is a summary of current ratings and recommmendations for Lyell Immunopharma and Century Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyell Immunopharma	1	1	6	1	2.78
Century Therapeutics	1	2	4	0	2.43

Lyell Immunopharma presently has a consensus price target of $40.86, indicating a potential upside of 172.38%. Century Therapeutics has a consensus price target of $4.75, indicating a potential upside of 214.57%. Given Century Therapeutics’ higher possible upside, analysts plainly believe Century Therapeutics is more favorable than Lyell Immunopharma.

Valuation and Earnings

This table compares Lyell Immunopharma and Century Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyell Immunopharma	$15,000.00	24,504.00	-$274.45 million	($12.56)	-1.19
Century Therapeutics	N/A	N/A	-$9.58 million	($0.93)	-1.62

Century Therapeutics has lower revenue, but higher earnings than Lyell Immunopharma. Century Therapeutics is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

About Lyell Immunopharma

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

About Century Therapeutics

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.